Article
Novel Therapeutic Targets and Biomarkers for the Treatment of Progressive Supranuclear Palsy
2020-06-12
Abstract excerpt
Progressive supranuclear palsy (PSP) is a sporadic parkinsonism tauopathy characterised by the deposition of aggregations of abnormal, hyperphosphorylated four-repeat tau (4R-tau). A revised clinical diagnostic criterion for PSP allows early presentations for the full spectrum of clinical phenotypes to be recognised enabling doctors to make a more accurate diagnosis. The major genetic risk factor for sporadic PSP...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- a28d4517-4d4e-54ad-ab7c-8cd99daa40cb
- DOI
- 10.20944/preprints202006.0147.v1